Development of a diagnostic method for chronic obstructive pulmonary disease (COPD) by quantification of two hyperoxidised forms of Prx2

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K07166
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: 湘南医療大学 (2021-2023); Meiji Pharmaceutical University (2020)
• Principal Investigator: Ishida Yo-ichi 湘南医療大学, 薬学部医療薬学科, 准教授 (90510454)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: Prx2 / 過酸化 / 赤血球 / 睡眠時無呼吸症候群 / 過酸化

Outline of Final Research Achievements

Peroxiredoxin 2 (Prx2) is a redox enzyme that acts in defence against oxidative stress in erythrocytes. It has been shown that the 51-cysteine of Prx2 is hyperoxidized to a sulphonic acid (-SO3H), but its clinical significance is unknown. Therefore, we investigated whether Prx2 hyperoxidation could be a biomarker for diagnosis in oxidative stress diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnoea syndrome (OSAS) (based on the collection of specimens, we proceeded to analyze OSAS). The results showed that Prx2 hyperoxidation was markedly increased in OSAS patients (healthy subjects as controls).

Translated with DeepL.com (free version)

Free Research Field

細胞生物学

Academic Significance and Societal Importance of the Research Achievements

本研究の学術的意義は、これまであまり機能解析が進んでいなかったPrx2に着目して、その臨床的な有用性を示した点にあると考えられる。今後、Prx2の過酸化型だけを検出するようなイムノアッセイ系を構築して、診断マーカーとしての有用性を示すことができれば、医療現場にも活用されることが期待されることから、その基礎段階となる本研究は、社会的意義も大きいと考えられる。